Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert
| A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor | 2007 |
|
Professor Alan Calvert Dr Fathi Azribi Rebecca Perrett Professor Ruth Plummer
| Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR | 2007 |
|
Dr Graham Dark Rebecca Perrett
| Deconstructing the construction of a learning module on practice development | 2007 |
|
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert
| Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers | 2007 |
|
Dr Graham Dark Rebecca Perrett
| Practice development - Part 1: Developing a practice initiative in oncology and palliative care | 2007 |
|
Dr Graham Dark Rebecca Perrett
| Practice development - Part 2: evaluating a practice initiative | 2007 |
|
Dr Graham Dark Rebecca Perrett
| Using e-learning as a tool for multidisciplinary education | 2007 |
|
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert
| A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours | 2006 |
|
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert
| Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR | 2006 |
|
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert
| A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors | 2005 |
|